Research Analysts Set Expectations for Moderna Q1 Earnings

Moderna, Inc. (NASDAQ:MRNA) – Stock analysts at Leerink Partnrs raised their Q1 2025 earnings per share (EPS) estimates for Moderna in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now anticipates that the company will earn ($3.60) per share for the quarter, up from their previous forecast of ($3.64). The consensus estimate for Moderna’s current full-year earnings is ($9.61) per share. Leerink Partnrs also issued estimates for Moderna’s Q2 2025 earnings at ($3.54) EPS, Q3 2025 earnings at ($1.88) EPS, Q4 2025 earnings at ($1.47) EPS, FY2025 earnings at ($10.46) EPS, FY2026 earnings at ($7.48) EPS and FY2027 earnings at ($4.86) EPS.

Several other equities analysts have also commented on MRNA. UBS Group decreased their price objective on Moderna from $96.00 to $78.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Evercore ISI set a $50.00 target price on shares of Moderna in a research report on Friday, February 14th. Bank of America lowered their price target on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and cut their price objective for the company from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Morgan Stanley lowered their target price on Moderna from $39.00 to $32.00 and set an “equal weight” rating for the company in a report on Wednesday, April 9th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $58.70.

Moderna Stock Down 1.9 %

Shares of NASDAQ MRNA opened at $24.72 on Friday. Moderna has a twelve month low of $23.15 and a twelve month high of $170.47. The firm has a market cap of $9.56 billion, a PE ratio of -2.66 and a beta of 2.23. The business has a fifty day simple moving average of $30.84 and a two-hundred day simple moving average of $39.81.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MRNA. Sentry Investment Management LLC purchased a new stake in shares of Moderna during the first quarter valued at $31,000. Wilmington Savings Fund Society FSB lifted its position in Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares during the period. Compass Planning Associates Inc purchased a new stake in Moderna during the 4th quarter valued at about $37,000. Venturi Wealth Management LLC increased its holdings in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock valued at $37,000 after purchasing an additional 664 shares during the period. Finally, Crowley Wealth Management Inc. purchased a new position in shares of Moderna in the fourth quarter worth about $41,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.